HGH Fragment 176-191 vs Efpeglenatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Frag 176-191, HGH Frag
HGH Fragment 176-191 is exactly what it sounds like: a short tail-end piece of the human growth hormone molecule, amino acids 176 through 191. The idea was to keep the fat-burning part of growth hormone while ditching the parts that raise blood sugar and IGF-1. The bare fragment has never been tested in a controlled human trial. Its modified cousin, AOD-9604, did go through real obesity trials, and the blunt result is that it was very safe but did not produce meaningful weight loss. It is banned in sport by WADA.
Also: Eppe, HM11260C
Efpeglenatide is a long-acting, once-weekly GLP-1 agonist from Hanmi Pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. Sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. Hanmi relaunched it for obesity, and on 7 October 2026 South Korea approved it as Eppe, the country's first homegrown GLP-1 obesity drug. It is not approved by the FDA or EMA.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Efpeglenatide has stronger research evidence (Human Trials) compared to HGH Fragment 176-191 (Animal Studies).
Detailed Comparison
| Attribute | HGH Fragment 176-191 | Efpeglenatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | This fragment is the C-terminal portion of growth hormone, the segment researchers linked to its effects on fat metabolism. The cleanest early data (Wu and Ng, 1993, rat fat tissue) found the closely related hGH 177-191 matched whole growth hormone at blocking new fat formation (antilipogenic) but had no significant direct fat-breakdown (lipolytic) effect. Later mouse work with AOD-9604 reported more fat oxidation, apparently without binding the growth hormone receptor itself. That is the selling point: because it does not act on the GH receptor, it does not raise IGF-1, does not promote tissue growth, and does not impair glucose handling the way full growth hormone can. Some research points to beta-3 adrenergic signaling in fat tissue, but the human mechanism is not nailed down. | Efpeglenatide activates the GLP-1 receptor, which raises insulin release after meals, lowers glucagon, slows stomach emptying and reduces appetite. The active part is an exendin-4 analog (the same parent peptide as exenatide and lixisenatide) attached through a small linker to a human IgG4 Fc fragment, using Hanmi's LAPSCOVERY platform. The Fc piece makes the molecule big enough to dodge kidney clearance and lets it recycle in the body, which stretches its half-life to weekly dosing. Hanmi argues its lower brain penetration explains the milder GI profile; that is a company argument rather than an independently proven fact. |
| Common Dosing | 250-500 mcg daily 1-2x daily, fasted | 10 mg once weekly maintenance (Korean label) Once weekly |
| Administration | Subcutaneous injection on empty stomach | Subcutaneous auto-injector once weekly |
| Typical Duration | 8-12 weeks | Long-term (chronic weight management); 40-64 weeks in the Korean phase 3 |
| Best Time to Take | Before bed or morning (fasted) | Same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The animal data looked promising and the human data deflated it, which is the whole story here. One caveat up front: every human result below comes from AOD-9604, the tyrosine-capped version, not the bare 176-191 fragment sold today. In obese mice (Endocrinology, 2001), both growth hormone and AOD-9604 reduced body-weight gain and increased fat oxidation, without the blood-sugar problems of full GH. A small 12-week phase 2 human study of AOD-9604 generated the early headline, with the 1 mg group losing modestly more weight than placebo. But the larger, better-powered phase 2b trial of roughly 500 obese adults over 24 weeks failed to show a significant weight-loss advantage over placebo, and the developer abandoned obesity development. What survived is the safety record: across about six trials and roughly 900 people, AOD-9604 was as well tolerated as placebo, with no IGF-1 rise and no glucose effects (Journal of Endocrinology and Metabolism, 2013). So the closest human data say safe, and not a meaningful fat-loss drug. | The strongest data come from Sanofi's AMPLITUDE-O trial (NEJM 2021), which enrolled people with type 2 diabetes and cardiovascular or kidney disease. Efpeglenatide 4 or 6 mg weekly cut major cardiovascular events by 27% versus placebo (7.0% vs 9.2%, hazard ratio 0.73) over a median of 1.8 years, and also reduced kidney outcomes. Sanofi still returned the rights in 2020 for business reasons. Hanmi then ran a Korean phase 3 obesity trial in 448 adults without diabetes (average BMI 32): at 40 weeks, weight loss was 9.02% versus 0.89% on placebo, and 75.1% lost at least 5%. That is less weight loss than semaglutide or tirzepatide in their pivotal trials, though trial designs differ, and GI side effects were somewhat lower (diarrhea 17.6%, nausea 16.6%, vomiting 11.6%). Korea's MFDS approved it for chronic weight management on 7 October 2026, with launch planned for late October. Bottom line: a solid, proven drug class member with real outcome data, but modest weight loss and no Western approval. |
Frequently Asked Questions: HGH Fragment 176-191 vs Efpeglenatide
What is the difference between HGH Fragment 176-191 and Efpeglenatide?
HGH Fragment 176-191 is a weight loss peptide that hgh fragment 176-191 is exactly what it sounds like: a short tail-end piece of the human growth hormone molecule, amino acids 176 through 191. the idea was to keep the fat-burning part of growth hormone while ditching the parts that raise blood sugar and igf-1. the bare fragment has never been tested in a controlled human trial. its modified cousin, aod-9604, did go through real obesity trials, and the blunt result is that it was very safe but did not produce meaningful weight loss. it is banned in sport by wada. Efpeglenatide is a weight loss peptide that efpeglenatide is a long-acting, once-weekly glp-1 agonist from hanmi pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. hanmi relaunched it for obesity, and on 7 october 2026 south korea approved it as eppe, the country's first homegrown glp-1 obesity drug. it is not approved by the fda or ema. The main differences lie in their mechanisms of action and clinical applications.
Which is better, HGH Fragment 176-191 or Efpeglenatide?
Neither is universally "better" - the choice depends on your specific goals. HGH Fragment 176-191 is typically used for weight loss purposes, while Efpeglenatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can HGH Fragment 176-191 and Efpeglenatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using HGH Fragment 176-191 and Efpeglenatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.